Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
FOR IMMEDIATE RELEASE Contacts: John W. Kozarich ActivX Biosciences, Inc. 858.558.5558 [email protected] James Forte or Kim Palmatier Townsend Inc. for ActivX 858.457.4888 [email protected] [email protected] ActivX Biosciences Announces Agreement with Gilead Sciences for Protein Activity Profiling LA JOLLA, California, April 6, 2004 – ActivX Biosciences, Inc., a privately held biotechnology company applying novel chemical technologies and high-throughput protein analysis to drug discovery and development, announced today it has entered into an agreement with Gilead Sciences of Foster City, California, USA to further characterize the activity of certain research compounds supplied by Gilead. Under the agreement, ActivX will utilize its proprietary technology to analyze specific proteins to provide a greater understanding of the biological activity of Gilead’s compounds. Financial terms of the agreement were not announced. “ActivX’s proprietary technology to rapidly and definitively characterize the activities of important protein families continues to generate excitement in the pharmaceutical industry. Our new agreement with Gilead provides ActivX with a unique opportunity to demonstrate the value of our technology to a leading biopharmaceutical company,” said John W. Kozarich, PhD., President and Chief Research & Development Officer of ActivX. With this partnership, ActivX continues to validate its technology by further building a strong portfolio of corporate partnerships, which currently include Kyorin Pharmaceutical Co. and Pfizer. ActivX Biosciences, Inc., based in La Jolla, California, is a privately held drug discovery and development company. ActivX’s proprietary chemical technologies and highthroughput protein analysis capabilities are being applied to advancing both its own internal drug pipeline as well as the development efforts of its pharmaceutical and biotechnology partners. By focusing specifically on functional proteins, ActivX addresses disease mechanisms directly; taking an approach that differs from that of traditional drug discovery and development methods. ActivX technology address critical challenges in drug discovery, such as selectivity profiling of drug candidates across entire protein families in biological samples to guide their medicinal chemistry optimization; identification of novel drug targets and biomarkers; and characterization of off-target activities of candidate and established drugs to understand the basis for their efficacy and toxicity. For more information on ActivX Biosciences, please visit the company’s Website at http://www.activx.com ###